Spots Global Cancer Trial Database for Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma
Official Title:
Study ID: NCT01021800
Conditions
Interventions
Study Description
Brief Summary: Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.
Detailed Description:
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Medical Centre Ljubljana, Department for Gastroenterolgy, Ljubljana, , Slovenia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
